Mesmerizing Video Shows Cardiac Cells Building a Heart
The images were captured using a technique called light-sheet microscopy (LSM). Essentially, LSM involves scanning a sample with a thin sheet of light, creating sharp, detailed, three-dimensional images of living tissue without damaging it.
Researchers from University College London (UCL) and the Francis Crick Institute in the UK used the method to track how mouse embryo cells begin to specialize into roles, divide, and arrange themselves into the structure of a heart.
The team tagged the different types of cells with fluorescent markers, then captured images of them every two minutes for up to 41 hours. The resulting timelapse shows a ragtag group of nondescript cells coming together to form a living, beating mouse heart in a way that's truly captivating to watch.
It's not just beautiful; it helped the team uncover new details about cardiac development. Surprisingly, individual cells seemed to already 'know' where they need to go and which roles they'll end up playing, even as early as four or five hours after the first embryonic cell divided.
"Our findings demonstrate that cardiac fate determination and directional cell movement may be regulated much earlier in the embryo than current models suggest," says Kenzo Ivanovitch, developmental biologist at UCL.
"This fundamentally changes our understanding of cardiac development by showing that what appears to be chaotic cell migration is actually governed by hidden patterns that ensure proper heart formation."
While it's a long way off from any practical benefits, a better understanding of this process could potentially lead to new treatment options for congenital heart defects, the team says.
The research was published in The EMBO Journal.
Scientists Peered Inside The Echidna's Mysterious 'Pseudo-Pouch'
Bizarre Three-Eyed Predator Hunted The Ocean Half a Billion Years Ago
Earth's Rotation Is Slowing Down, And It Might Explain Why We Have Oxygen
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
6 hours ago
- Medscape
Younger, Smaller Children Show Less Success With ART
Younger children living with HIV with low BMI for their age were more likely than older children to fail first-line antiretroviral therapy (ART), based on new data from the ODYSSEY trial presented at the International AIDS Society Conference on HIV Science. Although the ODYSSEY trial showed superior efficacy of dolutegravir (DTG)-based treatment than standard of care, data on predictors of treatment failure in children starting ART on DTG-based regimens are limited, wrote James Wyncoll, PhD, medical statistician at University College London, London, England, and colleagues in their abstract. The researchers reviewed data on 381 children who started first-line ART: 189 with DTG and 192 with standard of care. Most of the children (82%) were in Africa, 13% were in Thailand, and 5% were in Europe. At baseline, the median age of the children was 10.5 years, and the median CD4 percentage was 20%. The median BMI-for-age z-score was -0.58, and 19% of the participants met the World Health Organization (WHO) criteria for stage III/IV disease. The researchers considered the predictive values of baseline characteristics across four domains (anthropometrics, HIV indicators, hematology, and demographics) for treatment failure after 96 weeks. Overall, 75 children experienced treatment failure by 96 weeks, including 24 in the DTG group and 51 in the standard-of-care group. Fewer children treated with DTG experienced treatment failure and the risk declined with increasing age, the researchers wrote. However, predictors of treatment failure were not significantly different between treatment groups, they said. In the domain-specific models, after adjustment for weight and trial arm, independent and significant predictors of treatment failure included low BMI-for-age, low CD4%, WHO stage III/IV events, high neutrophils, and care at a location in Africa. In a multivariate analysis, DTG treatment, lower weight, CD4%, ongoing WHO stage III/IV events, and African region remained as significant predictors of treatment failure ( P < .1). Neutrophils were no longer significant after adjustment for ongoing WHO stage III/IV events, and BMI-for-age was no longer a significant predictor after adjustment for CD4% and region. 'The findings of this study can help clinicians by identifying characteristics at ART initiation which predict a child's risk of treatment failure,' Wyncoll told Medscape Medical News . This study provides information on predictors of treatment failure in children starting ART for the first time, including those starting DTG regimens, he said. Outside of clinical trials, adolescents receiving ART reportedly fared worse than younger children, but the current study showed that the risk for treatment failure declined with increasing age, Wyncoll said. 'We think it's likely that in trials, where participants have increased support, adolescents have good responses to treatment, and it is the youngest children who are at highest risk of treatment failure,' he noted. Reasons for greater treatment failure in younger children may include the need for different formulations, as well as the reliance on caregivers to administer the drugs, which can be difficult, he added. Both CD4% and BMI-for-age are previously recognized predictors of treatment failure. Takeaways and Next Steps The study's findings support previous research showing young age as a strong risk factor for treatment failure with ART, Wyncoll told Medscape Medical News. 'Even with early diagnosis and ART, other studies like the EARTH cohort and the LIFE trial show high mortality in the first 2 years of life, especially within the first 6 months,' he said. 'The EARTH study found that an adverse maternal social environment was linked to poorer outcomes and higher treatment failure in young children, emphasizing the need for strong, sustained support for mothers during pregnancy and early life of infants, including emotional and adherence support,' he noted. Screening for and preventing opportunistic infections such as tuberculosis and giving nutritional support is essential to promote treatment success, and baseline CD4 percentage can help identify children at highest risk for treatment failure, he said. The final model in the current study provides the basis for an online risk prediction tool for treatment failure, Wyncoll explained. Clinicians would enter a child's characteristics (such as treatment type, age, CD4%, and BMI for age) at ART initiation. 'Children are currently left behind when we consider novel treatment regimens,' Wyncoll said. 'Our work highlights the need for innovative approaches and more research into improved treatment for vulnerable children, such as different ART delivery methods or enhanced therapeutics,' he added. Although the researchers concluded that predictors of treatment failure for children in the DTG and SOC groups were the same, the findings were limited by the low rates of treatment failure for the children on DTG, Wyncoll told Medscape Medical News . 'Further research is needed using real-world data from children starting dolutegravir to consolidate these findings,' he said. Don't Discount DTG for Children Relatively few studies have examined risk factors for virologic failure in children with HIV, especially those on DTG, said Monica Gandhi, MD, director of the University of California San Francisco (UCSF) Bay Area Center for AIDS Research and professor of medicine at UCSF, in an interview. The current study findings showing a lower CD4 count when initiating ART or ongoing advanced HIV (as represented by the WHO stage III/IV events) or lower weight when starting ART were all risk factors for failure and were not unexpected, Gandhi told Medscape Medical News . 'What was surprising was to see DTG-based ART more associated with failure than standard-of-care (SoC) ART, since DTG is more potent and durable in adults,' she said. The clinical takeaway is to try to start ART in children as soon as possible to avoid low CD4 counts or more advanced HIV on ART, both of which are risk factors for failure, Gandhi said. DTG-based ART should still be the standard of care among children, but additional research is need to determine into what kind of formulations work best younger ages, such as a dispersible tablet for oral suspension, she added.
Associated Press
5 days ago
- Associated Press
New Study Raises Red Flags About Ingredients Found in Gas Station Heroin
Research conducted on dogs shows serious adverse effects at doses far lower than commonly sold amounts The Stop Gas Station Heroin coalition is sounding the alarm after reviewing a new animal study commissioned by CBD American Shaman, a Missouri-based company that sells '7' products in stores across the country. The study, which tested the effects of increasing doses of two lab-made substances — '7' (7-hydroxymitragynine) and 'Pseudo' (mitragynine pseudoindoxyl) — was funded to support the company's bid for FDA drug approval. But the research methods and results raise serious red flags for consumers of Gas Station Heroin. First, a clear conflict of interest occurred in conducting this study: CBD American Shaman has been illegally selling 7 products as dietary supplements since 2022, and the research was released by Holistic Alternative Recovery Trust (HART), a group with a financial stake in 7 and Pseudo products. Second, the study suggests these drugs may be far more dangerous than their labels imply: CBD American Shaman tells consumers that 7.5 milligrams, or half a tablet, is a safe serving. But based on the study's own data, that amount may be more than 25 times higher than what would be considered safe for human consumption. Using standard FDA methods to translate the effects seen in dogs to humans, Stop Gas Station Heroin estimates that just 0.3 milligrams could cross the threshold for risk. Yet many consumers of these products are unknowingly ingesting significantly greater amounts. Moreover, the study points to clear risks of addiction and dependency with misuse. 'These are not natural products. They are chemically altered, unapproved pharmaceutical drugs being marketed as herbal remedies,' said Matthew Lowe, Executive Director of Stop Gas Station Heroin. 'You can't just slap a 'dietary supplement' label on a drug and skip the safety trials.' CBD American Shaman and other purveyors of Gas Station Heroin have marketed 7 and Pseudo products as supplements formulated to cure, treat, and mitigate disease — namely, chronic pain and opioid use disorder — even though the products have never been approved by the FDA for any medical use. If companies like CBD American Shaman want to sell these substances legally, they must demonstrate the drugs' safety and effectiveness through a rigorous series of clinical trials and submit the results to the FDA as part of the New Drug Approval process. Until then, Stop Gas Station Heroin is calling for the immediate removal of these synthetic street drugs from store shelves. About Stop Gas Station Heroin Stop Gas Station Heroin is a national coalition that aims to educate consumers about harmful synthetic drugs and advocate for smart regulation that distinguishes between legitimate, natural botanicals and dangerous, synthetic drugs, combined with enforcement of current federal laws around unapproved drugs. To learn more, navigate to Media Contact Colby Wilson [email protected] ### SOURCE: Stop Gas Station Heroin Copyright 2025 EZ Newswire
Yahoo
6 days ago
- Yahoo
Britons smoke an estimated 28.6 billion cigarettes every year, study finds
An estimated 28.6 billion cigarettes are smoked in Britain each year, the equivalent of 78 million a day, according to new analysis. There are particularly high levels of consumption in more disadvantaged areas, with researchers calling for targeted public health efforts to tackle smoking rates. Charities warned the 'staggering figure' is a 'stark reminder of the deadly toll of inaction', and urged the Government to prioritise the Tobacco and Vapes Bill after Parliament's summer recess. The Cancer Research UK study, carried out by experts at University College London (UCL), used monthly Smoking Toolkit Study data from between 2022 and 2024. The analysis estimates adults who smoked consumed an average of 10.4 cigarettes per day, with 5.5% of those smoking more than 20 a day. Average consumption per smoker per year was 528 cigarettes, equating to 28.6 billion per year. Office for National Statistics (ONS) data suggests 11.9% adults in the UK – the equivalent of six million people – smoked in 2023, the lowest proportion since current records began in 2011. However, England could struggle to meet its smokefree target of 5% by 2030 if current trends continue, according to Cancer Research UK, with projections suggesting it may not be met until 2039. The study also highlighted inequalities in cigarette consumption in Britain. People from more deprived backgrounds smoked 11 cigarettes a day on average, compared to those in wealthier areas, who smoked 9.4 per day. Researchers also found people in the North East and Scotland smoked the most – 11.7 each – while people in London and the South West smoked the least, with 8.4 and 9.5 cigarettes respectively. Dr Sarah Jackson, research fellow at UCL's Institute of Epidemiology and Health Care, said bringing down consumption rates can improve public health and also help the environment. 'Tackling smoking is not just about preventing uptake among future generations,' she said. 'Supporting the six million people in the UK who currently smoke cigarettes to quit will have major benefits for public health and for the environment. 'Despite declining smoking rates, over 28 billion cigarettes are still consumed in Great Britain each year, generating up to 140,000 metric tons of toxic, non-biodegradable waste annually. 'Reducing cigarette consumption, particularly in the most affected regions and communities, is critical not only to save lives and narrow health inequalities, but also to protect our environment from one of the most pervasive forms of plastic pollution.' Dr Ian Walker, executive director of policy at Cancer Research UK, said: 'While great strides have been made to bring down smoking rates, we can't afford to be complacent. 'Every week, around 550 million cigarettes are still smoked in Britain – that's enough to fill an Olympic sized swimming pool. It's vital that everyone, wherever they live, can access the support they need to quit smoking for good.' Dr Walker described the Tobacco and Vapes Bill as 'a historic opportunity to help stub out the harms of smoking' but said it is frustrating the the legislation 'isn't progressing through Parliament as quickly as it should be'. The legislation – which cleared the House of Commons in March – will prevent anyone born on or after January 1 2009 from legally smoking if it becomes law. It is set to undergo further scrutiny in the House of Lords. However, around 20 billion cigarettes have been smoked in Britain since the bill was reintroduced in Commons in November last year, according to the analysis. Dr Walker added: 'Tobacco is a toxic product that should have no place in our future, and I urge all parliamentarians to back a smokefree UK and prioritise this Bill when it returns to the House of Lords. 'This world-leading legislation has strong political and public support that can't be ignored.' Reacting to the study, Hazel Cheeseman, chief executive of Action on Smoking and Health (Ash), said: 'Since Parliament last debated the Tobacco and Vapes Bill, an estimated 6.7 billion cigarettes have been smoked in the UK. 'That staggering figure is a stark reminder of the deadly toll of inaction. Every day that passes without this legislation is a day lost in protecting our children from addiction and improving public health. 'We urge the Government to make this Bill a priority immediately after summer recess. The country cannot afford further delay – this is a once-in-a-generation opportunity to create a smokefree future, and it must not be squandered.'
